English
简体中文
Total: £ 56.28
Published Date: 2024-03-29 | Pages: 96 | Tables: 192 | Medical Care
The global Chronic Liver Diseases Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Liver Diseases Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Liver Diseases Therapeutics.
Report Scope
The Chronic Liver Diseases Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Liver Diseases Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Liver Diseases Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
F. Hoffmann-La Roche
Merck
Novartis
Sanofi
Pfizer
Takeda Pharmaceutical
Bausch Health
Theratechnologies
Alnylam Pharmaceuticals
Protagonist Therapeutics
Dicerna Pharmaceuticals
Endo International
Provectus Biopharmaceuticals
MAX BioPharma
Segment by Type
Chemotherapy Drugs
Targeted Therapy
Vaccines
Antiviral Drugs
Immunoglobulins
Corticosteroids
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Liver Diseases Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Liver Diseases Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy Drugs
1.2.3 Targeted Therapy
1.2.4 Vaccines
1.2.5 Antiviral Drugs
1.2.6 Immunoglobulins
1.2.7 Corticosteroids
1.2.8 Others
1.3 Market by Application
1.3.1 Global Chronic Liver Diseases Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Liver Diseases Therapeutics Market Perspective (2019-2030)
2.2 Chronic Liver Diseases Therapeutics Growth Trends by Region
2.2.1 Global Chronic Liver Diseases Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Liver Diseases Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Chronic Liver Diseases Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Chronic Liver Diseases Therapeutics Market Dynamics
2.3.1 Chronic Liver Diseases Therapeutics Industry Trends
2.3.2 Chronic Liver Diseases Therapeutics Market Drivers
2.3.3 Chronic Liver Diseases Therapeutics Market Challenges
2.3.4 Chronic Liver Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Liver Diseases Therapeutics Players by Revenue
3.1.1 Global Top Chronic Liver Diseases Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Chronic Liver Diseases Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Liver Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Liver Diseases Therapeutics Revenue
3.4 Global Chronic Liver Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Chronic Liver Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Liver Diseases Therapeutics Revenue in 2023
3.5 Chronic Liver Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Chronic Liver Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Chronic Liver Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Liver Diseases Therapeutics Breakdown Data by Type
4.1 Global Chronic Liver Diseases Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Type (2025-2030)
5 Chronic Liver Diseases Therapeutics Breakdown Data by Application
5.1 Global Chronic Liver Diseases Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Liver Diseases Therapeutics Market Size (2019-2030)
6.2 North America Chronic Liver Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024)
6.4 North America Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Liver Diseases Therapeutics Market Size (2019-2030)
7.2 Europe Chronic Liver Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024)
7.4 Europe Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Liver Diseases Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Chronic Liver Diseases Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Liver Diseases Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Liver Diseases Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Liver Diseases Therapeutics Market Size (2019-2030)
9.2 Latin America Chronic Liver Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Liver Diseases Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Chronic Liver Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Pharma
11.1.1 Astellas Pharma Company Detail
11.1.2 Astellas Pharma Business Overview
11.1.3 Astellas Pharma Chronic Liver Diseases Therapeutics Introduction
11.1.4 Astellas Pharma Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.1.5 Astellas Pharma Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Introduction
11.2.4 Bristol-Myers Squibb Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Detail
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Chronic Liver Diseases Therapeutics Introduction
11.3.4 Gilead Sciences Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.3.5 Gilead Sciences Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Chronic Liver Diseases Therapeutics Introduction
11.4.4 GlaxoSmithKline Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.4.5 GlaxoSmithKline Recent Development
11.5 F. Hoffmann-La Roche
11.5.1 F. Hoffmann-La Roche Company Detail
11.5.2 F. Hoffmann-La Roche Business Overview
11.5.3 F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Introduction
11.5.4 F. Hoffmann-La Roche Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.5.5 F. Hoffmann-La Roche Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Chronic Liver Diseases Therapeutics Introduction
11.6.4 Merck Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Chronic Liver Diseases Therapeutics Introduction
11.7.4 Novartis Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Chronic Liver Diseases Therapeutics Introduction
11.8.4 Sanofi Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.8.5 Sanofi Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Chronic Liver Diseases Therapeutics Introduction
11.9.4 Pfizer Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Takeda Pharmaceutical
11.10.1 Takeda Pharmaceutical Company Detail
11.10.2 Takeda Pharmaceutical Business Overview
11.10.3 Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Introduction
11.10.4 Takeda Pharmaceutical Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.10.5 Takeda Pharmaceutical Recent Development
11.11 Bausch Health
11.11.1 Bausch Health Company Detail
11.11.2 Bausch Health Business Overview
11.11.3 Bausch Health Chronic Liver Diseases Therapeutics Introduction
11.11.4 Bausch Health Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.11.5 Bausch Health Recent Development
11.12 Theratechnologies
11.12.1 Theratechnologies Company Detail
11.12.2 Theratechnologies Business Overview
11.12.3 Theratechnologies Chronic Liver Diseases Therapeutics Introduction
11.12.4 Theratechnologies Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.12.5 Theratechnologies Recent Development
11.13 Alnylam Pharmaceuticals
11.13.1 Alnylam Pharmaceuticals Company Detail
11.13.2 Alnylam Pharmaceuticals Business Overview
11.13.3 Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Introduction
11.13.4 Alnylam Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.13.5 Alnylam Pharmaceuticals Recent Development
11.14 Protagonist Therapeutics
11.14.1 Protagonist Therapeutics Company Detail
11.14.2 Protagonist Therapeutics Business Overview
11.14.3 Protagonist Therapeutics Chronic Liver Diseases Therapeutics Introduction
11.14.4 Protagonist Therapeutics Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.14.5 Protagonist Therapeutics Recent Development
11.15 Dicerna Pharmaceuticals
11.15.1 Dicerna Pharmaceuticals Company Detail
11.15.2 Dicerna Pharmaceuticals Business Overview
11.15.3 Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Introduction
11.15.4 Dicerna Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.15.5 Dicerna Pharmaceuticals Recent Development
11.16 Endo International
11.16.1 Endo International Company Detail
11.16.2 Endo International Business Overview
11.16.3 Endo International Chronic Liver Diseases Therapeutics Introduction
11.16.4 Endo International Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.16.5 Endo International Recent Development
11.17 Provectus Biopharmaceuticals
11.17.1 Provectus Biopharmaceuticals Company Detail
11.17.2 Provectus Biopharmaceuticals Business Overview
11.17.3 Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Introduction
11.17.4 Provectus Biopharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.17.5 Provectus Biopharmaceuticals Recent Development
11.18 MAX BioPharma
11.18.1 MAX BioPharma Company Detail
11.18.2 MAX BioPharma Business Overview
11.18.3 MAX BioPharma Chronic Liver Diseases Therapeutics Introduction
11.18.4 MAX BioPharma Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024)
11.18.5 MAX BioPharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Chronic Liver Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Chemotherapy Drugs
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Vaccines
Table 5. Key Players of Antiviral Drugs
Table 6. Key Players of Immunoglobulins
Table 7. Key Players of Corticosteroids
Table 8. Key Players of Others
Table 9. Global Chronic Liver Diseases Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Chronic Liver Diseases Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Chronic Liver Diseases Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global Chronic Liver Diseases Therapeutics Market Share by Region (2019-2024)
Table 13. Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global Chronic Liver Diseases Therapeutics Market Share by Region (2025-2030)
Table 15. Chronic Liver Diseases Therapeutics Market Trends
Table 16. Chronic Liver Diseases Therapeutics Market Drivers
Table 17. Chronic Liver Diseases Therapeutics Market Challenges
Table 18. Chronic Liver Diseases Therapeutics Market Restraints
Table 19. Global Chronic Liver Diseases Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global Chronic Liver Diseases Therapeutics Market Share by Players (2019-2024)
Table 21. Global Top Chronic Liver Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Liver Diseases Therapeutics as of 2023)
Table 22. Ranking of Global Top Chronic Liver Diseases Therapeutics Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by Chronic Liver Diseases Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Chronic Liver Diseases Therapeutics Product Solution and Service
Table 26. Date of Enter into Chronic Liver Diseases Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Chronic Liver Diseases Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Type (2019-2024)
Table 30. Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Type (2025-2030)
Table 32. Global Chronic Liver Diseases Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Application (2019-2024)
Table 34. Global Chronic Liver Diseases Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Application (2025-2030)
Table 36. North America Chronic Liver Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe Chronic Liver Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific Chronic Liver Diseases Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific Chronic Liver Diseases Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific Chronic Liver Diseases Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America Chronic Liver Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa Chronic Liver Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa Chronic Liver Diseases Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa Chronic Liver Diseases Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 51. Astellas Pharma Company Detail
Table 52. Astellas Pharma Business Overview
Table 53. Astellas Pharma Chronic Liver Diseases Therapeutics Product
Table 54. Astellas Pharma Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 55. Astellas Pharma Recent Development
Table 56. Bristol-Myers Squibb Company Detail
Table 57. Bristol-Myers Squibb Business Overview
Table 58. Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Product
Table 59. Bristol-Myers Squibb Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 60. Bristol-Myers Squibb Recent Development
Table 61. Gilead Sciences Company Detail
Table 62. Gilead Sciences Business Overview
Table 63. Gilead Sciences Chronic Liver Diseases Therapeutics Product
Table 64. Gilead Sciences Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 65. Gilead Sciences Recent Development
Table 66. GlaxoSmithKline Company Detail
Table 67. GlaxoSmithKline Business Overview
Table 68. GlaxoSmithKline Chronic Liver Diseases Therapeutics Product
Table 69. GlaxoSmithKline Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 70. GlaxoSmithKline Recent Development
Table 71. F. Hoffmann-La Roche Company Detail
Table 72. F. Hoffmann-La Roche Business Overview
Table 73. F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Product
Table 74. F. Hoffmann-La Roche Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 75. F. Hoffmann-La Roche Recent Development
Table 76. Merck Company Detail
Table 77. Merck Business Overview
Table 78. Merck Chronic Liver Diseases Therapeutics Product
Table 79. Merck Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 80. Merck Recent Development
Table 81. Novartis Company Detail
Table 82. Novartis Business Overview
Table 83. Novartis Chronic Liver Diseases Therapeutics Product
Table 84. Novartis Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 85. Novartis Recent Development
Table 86. Sanofi Company Detail
Table 87. Sanofi Business Overview
Table 88. Sanofi Chronic Liver Diseases Therapeutics Product
Table 89. Sanofi Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 90. Sanofi Recent Development
Table 91. Pfizer Company Detail
Table 92. Pfizer Business Overview
Table 93. Pfizer Chronic Liver Diseases Therapeutics Product
Table 94. Pfizer Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 95. Pfizer Recent Development
Table 96. Takeda Pharmaceutical Company Detail
Table 97. Takeda Pharmaceutical Business Overview
Table 98. Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Product
Table 99. Takeda Pharmaceutical Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 100. Takeda Pharmaceutical Recent Development
Table 101. Bausch Health Company Detail
Table 102. Bausch Health Business Overview
Table 103. Bausch Health Chronic Liver Diseases Therapeutics Product
Table 104. Bausch Health Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 105. Bausch Health Recent Development
Table 106. Theratechnologies Company Detail
Table 107. Theratechnologies Business Overview
Table 108. Theratechnologies Chronic Liver Diseases Therapeutics Product
Table 109. Theratechnologies Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 110. Theratechnologies Recent Development
Table 111. Alnylam Pharmaceuticals Company Detail
Table 112. Alnylam Pharmaceuticals Business Overview
Table 113. Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Product
Table 114. Alnylam Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 115. Alnylam Pharmaceuticals Recent Development
Table 116. Protagonist Therapeutics Company Detail
Table 117. Protagonist Therapeutics Business Overview
Table 118. Protagonist Therapeutics Chronic Liver Diseases Therapeutics Product
Table 119. Protagonist Therapeutics Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 120. Protagonist Therapeutics Recent Development
Table 121. Dicerna Pharmaceuticals Company Detail
Table 122. Dicerna Pharmaceuticals Business Overview
Table 123. Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Product
Table 124. Dicerna Pharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 125. Dicerna Pharmaceuticals Recent Development
Table 126. Endo International Company Detail
Table 127. Endo International Business Overview
Table 128. Endo International Chronic Liver Diseases Therapeutics Product
Table 129. Endo International Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 130. Endo International Recent Development
Table 131. Provectus Biopharmaceuticals Company Detail
Table 132. Provectus Biopharmaceuticals Business Overview
Table 133. Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Product
Table 134. Provectus Biopharmaceuticals Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 135. Provectus Biopharmaceuticals Recent Development
Table 136. MAX BioPharma Company Detail
Table 137. MAX BioPharma Business Overview
Table 138. MAX BioPharma Chronic Liver Diseases Therapeutics Product
Table 139. MAX BioPharma Revenue in Chronic Liver Diseases Therapeutics Business (2019-2024) & (US$ Million)
Table 140. MAX BioPharma Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chronic Liver Diseases Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Chronic Liver Diseases Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Chemotherapy Drugs Features
Figure 4. Targeted Therapy Features
Figure 5. Vaccines Features
Figure 6. Antiviral Drugs Features
Figure 7. Immunoglobulins Features
Figure 8. Corticosteroids Features
Figure 9. Others Features
Figure 10. Global Chronic Liver Diseases Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global Chronic Liver Diseases Therapeutics Market Share by Application: 2023 VS 2030
Figure 12. Hospital Pharmacies Case Studies
Figure 13. Retail Pharmacies Case Studies
Figure 14. Online Pharmacies Case Studies
Figure 15. Chronic Liver Diseases Therapeutics Report Years Considered
Figure 16. Global Chronic Liver Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Chronic Liver Diseases Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Chronic Liver Diseases Therapeutics Market Share by Region: 2023 VS 2030
Figure 19. Global Chronic Liver Diseases Therapeutics Market Share by Players in 2023
Figure 20. Global Top Chronic Liver Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Liver Diseases Therapeutics as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Chronic Liver Diseases Therapeutics Revenue in 2023
Figure 22. North America Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Chronic Liver Diseases Therapeutics Market Share by Country (2019-2030)
Figure 24. United States Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Chronic Liver Diseases Therapeutics Market Share by Country (2019-2030)
Figure 28. Germany Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Chronic Liver Diseases Therapeutics Market Share by Region (2019-2030)
Figure 36. China Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Chronic Liver Diseases Therapeutics Market Share by Country (2019-2030)
Figure 44. Mexico Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Chronic Liver Diseases Therapeutics Market Share by Country (2019-2030)
Figure 48. Turkey Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Chronic Liver Diseases Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Astellas Pharma Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 51. Bristol-Myers Squibb Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 52. Gilead Sciences Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 53. GlaxoSmithKline Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 54. F. Hoffmann-La Roche Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 55. Merck Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 56. Novartis Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 57. Sanofi Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 58. Pfizer Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 59. Takeda Pharmaceutical Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 60. Bausch Health Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 61. Theratechnologies Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 62. Alnylam Pharmaceuticals Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 63. Protagonist Therapeutics Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 64. Dicerna Pharmaceuticals Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 65. Endo International Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 66. Provectus Biopharmaceuticals Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 67. MAX BioPharma Revenue Growth Rate in Chronic Liver Diseases Therapeutics Business (2019-2024)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
